Opinion|Videos|March 13, 2025
Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy
Author(s)Lori J. Wirth, MD
A panelist discusses how immunotherapy combined with chemotherapy has revolutionized recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment through improved survival outcomes demonstrated in landmark trials such as JUPITER-02 with toripalimab and KEYNOTE-590 with pembrolizumab, emphasizing that although most patients benefit regardless of PD-L1 status or Epstein-Barr virus positivity, clinicians must carefully consider patient-specific factors, such as performance status and comorbidities, alongside the management of unique immune-related adverse events through early recognition, established treatment algorithms, and multidisciplinary collaboration to optimize outcomes in this evolving treatment landscape.
Episodes in this series
Video content above is prompted by the following:
- Please further elaborate on your clinical experience and perception of immunotherapy in combination with chemotherapy for R/M NPC.
- What are your thoughts on the use of other immunotherapy agents, such as pembrolizumab?
- Overall, how do you see immunotherapy impacting the treatment landscape for R/M NPC?
- How would you determine which patients are best suited for immunotherapy?
- How do you foresee clinical practice adapting to incorporate immunotherapies?
- What factors are critical to consider when integrating immunotherapy into treatment protocols for R/M NPC?
- Please discuss other treatment considerations to consider with recurrent NPC.
- Please discuss potential adverse events and strategies to mitigate/manage risks.
Related Content
Advertisement
